Acute and chronic kidney function decline in patients receiving BRAF/MEK inhibitors for melanoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Acute and chronic kidney function decline in patients receiving BRAF/MEK inhibitors for melanoma

Published:2024-02-22 Issue:6 Volume:39 Page:1040-1043
ISSN:0931-0509
Container-title:Nephrology Dialysis Transplantation
language:en
Short-container-title:

Author:

Mistry Kavita¹²,Zhao Sophia³,Strohbehn Ian⁴,Wang Qiyu⁴^ORCID,Hanna Paul⁴⁵^ORCID,Strohbehn Samuel⁴,Katz-Agranov Nurit⁴,Sullivan Ryan J⁶,Sise Meghan E⁴

Affiliation:

1. Department of Medicine, Division of Nephrology, Beth Israel Deaconess Medical Center , Boston, MA , USA

2. Department of Medicine, Brigham and Women's Hospital , Boston, MA , USA

3. Analytica Now LLC , Brookline, MA , USA

4. Department of Medicine, Division of Nephrology, Massachusetts General Hospital , Boston, MA , USA

5. Department of Medicine, Division of Nephrology, Medical College of Wisconsin , Milwaukee, WI , USA

6. Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital , Boston, MA , USA

Funder

Merck

Publisher

Oxford University Press (OUP)

Link

https://academic.oup.com/ndt/advance-article-pdf/doi/10.1093/ndt/gfae049/56907966/gfae049.pdf

Reference16 articles.

1. Survival of patients with advanced metastatic melanoma: the impact of novel therapies;Ugurel;Eur J Cancer,2016

2. Treatment of advanced metastatic melanoma;Quaglino;Dermatol Pract Concept,2021

3. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial;Grob;Lancet Oncol,2015

4. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial;Long;Lancet,2015

5. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial;Dummer;Lancet Oncol,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3